retatrutide clinical trials safety efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Triple hormone receptor agonist retatrutide

When interpreted together with the findings of the STEP 4 withdrawal trial and STEP 1 off-treatment extension study, which both showed weight regain after semaglutide discontinuation (after 20 weeks treatment in STEP 4 and 68 weeks treatment in STEP 1) 23,24 , these results support the benefit of continued semaglutide treatment for sustained weight loss

If you havent lost at least 5% body weight by week 12, discuss dose escalation with your physician

The scale was stalling because I was simultaneously losing fat and holding more water temporarily

The two drugs may share a pharmacological category, but their safety profiles are not equivalent

However, women managing both conditions need more frequent monitoring and may need coordinated care between endocrinology and gynecology

The statutory framework for compounding has always been limited, and as supply and access to approved products evolve, so too does the Agencys enforcement posture